Comparison of the Performance of an Optimized 3D EPI SWI Sequence and a Non-EPI QSM SWI Sequence in Detecting the Central Vein Sign in Patients With Multiple Sclerosis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04705870

Acronym

COPEQ-MS

Enrollment

Registered

2021-01-12

Start date

2021-06-02

Completion date

2023-05-24

Last updated

2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Brief summary

Patients who have agreed to participate in the study will complete the MRI protocol as part of routine care, to which four additional 20-minute sequences will be added. MRI of routine care in the context of MS includes at least the following sequences: * 3D T1 TFE (2 minutes) * T2 TSE (2 minutes) * 3D FLAIR (3 minutes) * SWI EPI 0.6 iso (7 minutes) The sequences added by the search are: * SWI non EPI QSM 6 echo (10 minutes) * SWI EPI in resolution equivalent to non-EPI SWI (3 minutes) * SWI EPI to TR equivalent to SWI non EPI (6 minutes) These sequences will be acquired before or after the injection of gadolinium (if present in the examination of routine care). For examinations carried out with injection, the order of carrying out the 4 post-injection SWI sequences will be random.

Interventions

DEVICEcerebral MRI

MRI of routine care in the context of MS includes at least the following sequences: * 3D T1 TFE (2 minutes) * T2 TSE (2 minutes) * 3D FLAIR (3 minutes) * SWI EPI 0.6 iso (7 minutes) The sequences added by the search are: * SWI non EPI QSM 6 echo (10 minutes) * SWI EPI in resolution equivalent to non-EPI SWI (3 minutes) * SWI EPI to TR equivalent to SWI non EPI (6 minutes)

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients over 18 * With MS defined according to the McDonald's revised clinical or radiological spatial and temporal dissemination criteria, with onset of symptoms \<5 years * To benefit as part of care from an MRI with or without injection of gadolinium * Express consent to participate in the study * Affiliate or beneficiary of a social security scheme

Exclusion criteria

* Patient benefiting from a legal protection measure * Pregnant or breastfeeding woman

Design outcomes

Primary

Measure	Time frame
percentage of lesions showing the central vein sign with the SWI EPI sequence that also show the central vein sign with the candidate sequence	1 day
percentage of lesions which do not present the sign of the central vein with the SWI EPI sequence but which present it with the candidate sequence	1 day

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026